Novacyt: never a dull moment but time for greater clarity
News that a dispute with the DHSC extends to sales made in the 1st quarter of 2021 has pulled the shares down again, although, as we suggested previously, this was surely to be expected. Novacyt now needs to provide greater clarity on 2020 financial results and its current financial position, lawyers notwithstanding!
Shares in clinical diagnostics group Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), tumbled further after an update on its ongoing dispute with the Department of Health and Social Care (‘DHSC’).
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on Novacyt SA
A refocused business delivers
Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…
Better than expected
Some welcome good news at last for shareholders in this provider of online competitions to win…
